An abstract embodying our novel method and research results was published by the American Society of Clinical Oncology (ASCO) on May 26, 2022. The results of our study were presented at the ASCO Annual Meeting in June 2022 with over 40,000 attendees.

Highlights of the abstract include: 

• Antibodies generated against a specific type of cancer can kill those cancer cells without harming normal cells from the same tissue type and the same person.
• These antibodies against one person’s cancer can kill the same cancer type from a different person.
• These antibodies surprisingly can also kill cancer cells of a different type than the kind they were derived against.
• Antibodies generated against one person’s cancer do not harm normal cells from a different person.
• The platform can generate antibodies against a variety of cancers.